Biote Corp. Form 8-K Summary
Business Context and Reporting Period
Biote Corp. filed a Form 8-K dated August 25, 2022, under Item 7.01 (Regulation FD Disclosure). The filing reports a securities-listing development rather than quarterly or annual financial results.
Material Event
- The company announced approval of its application to relist its Class A common stock and warrants on The Nasdaq Stock Market LLC.
- The securities were scheduled to begin trading at the open of trading on August 29, 2022.
- The securities were to retain the existing symbols: Class A common stock, BTMD; warrants, BTMDW.
- Before the relisting, the securities were identified as trading on the OTC Pink Open Market.
Financial Metrics and Capital Structure
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, guidance, or other operating and financial metrics. No clear comparable-period financial information is included.
Management Commentary, Risks, and Unusual Items
The filing contains no detailed management outlook or risk discussion. The relisting is subject to the stated Nasdaq approval and scheduled trading date. The attached press release is furnished under Regulation FD and is not deemed filed for purposes of Section 18 of the Exchange Act or incorporated by reference into other filings.
Important Facts to Verify
- Whether trading on Nasdaq commenced as scheduled on August 29, 2022.
- Whether the Class A common stock and warrants continued under symbols BTMD and BTMDW.
- The applicable Nasdaq listing status and any subsequent listing or trading notices.
- Any later filings providing financial results, liquidity information, or material risks not addressed in this 8-K.